Abstract
In the last decades, the cannabinoid system (comprising synthetic and endogenous cannabinoid agonists and antagonists, their receptors and degrading enzymes) has been shown to induce potent immunomodulatory activities in atherogenesis and acute ischemic complications. Different from the other cannabinoid receptors in which controversial results are reported, the selective activation of the cannabinoid receptor type 2 (CB2) has been shown to play antiinflammatory and protective actions within atherosclerotic vessels and downstream ischemic peripheral organs. CB2 is a transmembrane receptor that triggers protective intracellular pathways in cardiac, immune and vascular cells in both human and animal models of atherosclerosis. Considering basic research data, medications activating CB2 function in the circulation or peripheral target organs might be a promising approach against atherogenesis. This review updates evidence from preclinical studies on different CB2-triggered pathways in atherosclerosis and acute ischemic events.
Keywords: Atherosclerosis, cannabinoids, CB2, ischemia/reperfusion injury, ischemic stroke.
Current Medicinal Chemistry
Title:Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Volume: 21 Issue: 35
Author(s): Federico Carbone, Francois Mach, Nicolas Vuilleumier and Fabrizio Montecucco
Affiliation:
Keywords: Atherosclerosis, cannabinoids, CB2, ischemia/reperfusion injury, ischemic stroke.
Abstract: In the last decades, the cannabinoid system (comprising synthetic and endogenous cannabinoid agonists and antagonists, their receptors and degrading enzymes) has been shown to induce potent immunomodulatory activities in atherogenesis and acute ischemic complications. Different from the other cannabinoid receptors in which controversial results are reported, the selective activation of the cannabinoid receptor type 2 (CB2) has been shown to play antiinflammatory and protective actions within atherosclerotic vessels and downstream ischemic peripheral organs. CB2 is a transmembrane receptor that triggers protective intracellular pathways in cardiac, immune and vascular cells in both human and animal models of atherosclerosis. Considering basic research data, medications activating CB2 function in the circulation or peripheral target organs might be a promising approach against atherogenesis. This review updates evidence from preclinical studies on different CB2-triggered pathways in atherosclerosis and acute ischemic events.
Export Options
About this article
Cite this article as:
Carbone Federico, Mach Francois, Vuilleumier Nicolas and Montecucco Fabrizio, Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases, Current Medicinal Chemistry 2014; 21 (35) . https://dx.doi.org/10.2174/0929867321666140915141332
DOI https://dx.doi.org/10.2174/0929867321666140915141332 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Taurine, Bone Growth and Bone Development
Current Nutrition & Food Science Interrelationship Between Kidney Function and Percutaneous Mitral Valve Interventions: A Comprehensive Review
Current Cardiology Reviews Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Emerging Concepts for Myocardial Late Gadolinium Enhancement MRI
Current Cardiology Reviews Editorial (Thematic Issues: Pharmacological Mechanisms and Interventions in Ischemia/ Reperfusion-Induced Injury)
Current Pharmaceutical Design Cardiomyocyte-Specific TβR2 Knockout Mice are More Susceptible to Cardiac Hypertrophy Induced by Adrenergic Agonist Stimulation
Current Molecular Medicine PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Adipose Triglyceride Lipase: A New Target in the Regulation of Lipolysis by Insulin
Current Diabetes Reviews New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrinemediated Tissue Repair
Current Stem Cell Research & Therapy Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets